# Clinical Trial of the Use of Anakinra in Cytokine Storm Syndrome Secondary to Covid-19 (ANA-COVID-GEAS)

> **NCT04443881** · PHASE2,PHASE3 · COMPLETED · sponsor: **Fundacion Miguel Servet** · enrollment: 179 (actual)

## Conditions studied

- COVID-19 Pnemonia

## Interventions

- **DRUG:** Anakinra 149 MG/ML Prefilled Syringe [Kineret]

## Key facts

- **NCT ID:** NCT04443881
- **Lead sponsor:** Fundacion Miguel Servet
- **Sponsor class:** OTHER
- **Phase:** PHASE2,PHASE3
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2020-05-08
- **Primary completion:** 2021-03-31
- **Final completion:** 2021-03-31
- **Target enrollment:** 179 (ACTUAL)
- **Last updated:** 2021-06-01


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT04443881

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT04443881, "Clinical Trial of the Use of Anakinra in Cytokine Storm Syndrome Secondary to Covid-19 (ANA-COVID-GEAS)". Retrieved via AI Analytics 2026-08-18 from https://api.ai-analytics.org/clinical/NCT04443881. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*